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Abstract
Background: Studies show that electroacupuncture (EA) has beneficial effects in patients with
inflammatory diseases. This study investigated the mechanisms of EA anti-inflammation, using a rat
model of complete Freund's adjuvant (CFA)-induced hind paw inflammation and hyperalgesia.
Design: Four experiments were conducted on male Sprague-Dawley rats (n = 6–7/per group).
Inflammation was induced by injecting CFA into the plantar surface of one hind paw. Experiment 1
examined whether EA increases plasma adrenocorticotropic hormone (ACTH) levels.
Experiments 2 and 3 studied the effects of the ACTH and corticotropin-releasing hormone (CRH)
receptor antagonists, ACTH(11–24) and astressin, on the EA anti-edema. Experiment 4 determined
whether EA activates CRH neurons in the paraventricular nucleus of the hypothalammus. EA
treatment, 10 Hz at 3 mA and 0.1 ms pulse width, was given twice for 20 min each, once
immediately post and again 2 hr post-CFA. Plasma ACTH levels, paw thickness, and paw withdrawal
latency to a noxious thermal stimulus were measured 2 h and 5 h after the CFA.
Results: EA significantly increased ACTH levels 5 h (2 folds) after CFA compared to sham EA
control, but EA alone in naive rats and CFA alone did not induce significant increases in ACTH.
ACTH(11–24) and astressin blocked EA anti-edema but not EA anti-hyperalgesia. EA induced
phosphorylation of NR1, an essential subunit of the N-methyl-D-aspartic acid (NMDA) receptor,
in CRH-containing neurons of the paraventricular nucleus.
Conclusion: The data demonstrate that EA activates CRH neurons to significantly increase plasma
ACTH levels and suppress edema through CRH and ACTH receptors in a rat model of
inflammation.
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1. Background
Clinical trials show that electroacupuncture (EA) has ben-
eficial effects in patients with various inflammatory dis-
eases [1]. Studies demonstrate that EA significantly
inhibits complete Freund's adjuvant (CFA)-induced hind
paw inflammation and hyperalgesia in a rat model [2,3].
However, the underlying mechanisms of acupuncture are
still not completely understood.
We recently demonstrated that EA significantly increased
plasma corticosterone levels in rats with hind paw inflam-
mation compared to sham EA control. Adrenalectomy
blocked EA-produced anti-edema, but not EA anti-hyper-
algesia. RU486, a prototypical glucocorticoid receptor
antagonist, also prevented EA anti-edema. These data sug-
gest that adrenal gland-secreted corticosterone mediates
EA anti-edema [2,4].
Previous study suggests that the paraventricular nucleus
(PVN) of the hypothalamus is involved in acupuncture
analgesia. Electrical stimulation of the PVN significantly
increased the pain threshold and enhanced acupuncture
analgesia [5]. Pituitary gland involvement in EA has been
inconclusive. It was reported that hypophysectomy
(HYPOX) attenuated acupuncture analgesia in mice [6]
and rats [7,8], and that inhibition of the pituitary function
by dexamethasone treatment reduced acupuncture anal-
gesia [9]. These data indicate the involvement of the pitu-
itary gland in EA analgesia. However, it was also reported
that HYPOX did not alter EA-induced inhibition of the
writhing response in mice [10] and that the pituitary
gland was not involved in production of EA analgesia in
rats [11]. These discrepancies are likely related to the sta-
tus of the animals (e.g. length of time after surgery) and to
the tests used in the studies. All of these studies were con-
ducted on animals with mechanical or chemical pituitary
gland damage and transient noxious stimuli. Corticotro-
pin-releasing factor (CRH) and adrenocorticotropic hor-
mone (ACTH) are secreted by the PVN and pituitary
gland, respectively, and drive the secretion of corticoster-
one from adrenal glands. Whether they are involved in
EA-produced anti-edema and anti-hyperalgesia has not
been previously investigated using their respective antag-
onists in an inflammatory pain animal model. Because
uninjured models do not mimic the chronic pathological
conditions seen clinically, we used a CFA-inflamed rat
model to test the hypothesis that EA activates CRH-con-
taining neurons in the PVN and increases plasma ACTH
levels to ameliorate inflammation and hyperalgesia.
2. Methods
2.1 Animal preparation
Male Sprague-Dawley rats weighing 280–320 g (Harlan,
Indianapolis, IN) were kept under controlled conditions
(22°C, relative humidity 40%–60%, 12-hour alternate
light-dark cycles, food and water ad libitum). The animal
protocols were approved by the Institutional Animal Care
and Use Committee (IACUC) of the University of Mary-
land School of Medicine.
2.2 Experimental design
Four experiments were conducted. In Experiment 1 we
measured plasma ACTH levels to examine whether EA reg-
ulates ACTH secretion. Rats were divided into four groups
(n = 6 per group): CFA (0.08 ml) + EA, CFA + sham EA,
CFA + no treatment, and naive + EA. EA was administered
at 10 Hz, 3 mA, 0.1 ms pulse width for two 20-min peri-
ods, once at the beginning and once at the end of a 2-h
period starting immediately after CFA injection. Blood
samples (0.5 ml) were taken from each rat at baseline
(before inflammation and/or EA) and 2 h and 5 h after
inflammation. In Experiment 2, an ACTH antagonist,
ACTH(11–24) (Bachem), was used to study the effects of
ACTH on the therapeutic actions of EA. Rats were divided
into four groups (n = 7 per group): 1) CFA (0.06 ml) +
Vehicle + Sham EA, 2) CFA + Vehicle + EA, 3) CFA +
ACTH(11–24) + Sham EA and 4) CFA + ACTH(11–24) + EA. A
2 mg/ml concentration of ACTH(11–24) was dissolved in
saline, and 2 mg/kg of ACTH(11–24) or vehicle was intrave-
nously (i.v.) injected 5 min before each of two 10 Hz EA
treatments. The degree of edema, indicative of the inten-
sity of inflammation, was quantified by measuring paw
thickness with a Laser Sensor (AR200-50, Acuity, Port-
land, OR) 2 h and 5 h after a CFA injection into a hind
paw. The paw withdrawal latency (PWL) test was con-
ducted at the same time points. The investigator who con-
ducted the measurement was blinded to the treatment
assignments. Experiment 3 was to determine whether a
CRH receptor antagonist, astressin, influences EA action.
CFA-inflamed rats were divided into four groups (n = 7
per group): 1) CFA + Vehicle + Sham EA, 2) CFA + Vehicle
+ EA, 3) CFA + Astressin (Sigma) + Sham EA and 4) CFA
+ Astressin + EA. The paw thickness was measured with
the same Laser Sensor. A 2 mg/ml concentration of ast-
ressin was dissolved in saline, and 0.2 mg/kg of astressin
or vehicle was injected (i.v.) 5 min before each of two 10
Hz EA treatments. Experiment 4 was to determine
whether EA activates CRH-containing neurons in the
PVN. This was done by demonstrating double-labeling of
CRH and phosphorylated NR1, an essential subunit of the
N-methyl-D-aspartic acid (NMDA) receptor, the phos-
phorylation of which is known to modulate NMDA recep-
tor activity and can be used as an indicator of NMDA
receptor activation. To avoid the effect of CFA-induced
inflammation on the PVN neurons, 3 naive rats given EA
treatment and 2 untreated naive rats were used in this
experiment.BMC Complementary and Alternative Medicine 2008, 8:20 http://www.biomedcentral.com/1472-6882/8/20
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2.3 Intravenous cannulation and blood sample collection
For intravenous cannulation, animals were anesthetized
with sodium pentobarbital (50 mg/kg) intraperitoneally
(i.p.) and surgically implanted with a subcutaneous jugu-
lar catheter (Braintree Scientific, Inc). The catheter was
secured with Mersilene surgical mesh (General Medical,
New Haven, CT) at the jugular vein. It exited at the ani-
mal's back through a 22-gauge tubing secured with mesh.
Antibiotic ointment was applied to the wound. To prevent
clogging, catheters were flushed every third day with 0.15
ml of gentamicin (120 µg/ml). At baseline and 2 h and 5
h post-CFA, 0.5 ml of blood was withdrawn, and the lost
volume was replaced by an equal volume of saline. Blood
was centrifuged (1310 g) for 15 min at 4°C. The plasma
was collected and stored at -80°C until assayed. ACTH
levels were measured with a commercially available ELISA
kit (MD Biosciences, Inc.) using the procedure recom-
mended by the manufacturer. The detection limit of the
kit is 0.46 pg/ml. The antibody in the kit specifically reacts
with ACTH and has less than 1% cross-reactivity with
alpha-MSH (Melanocyte-stimulating hormone) and beta-
endorphin. ACTH concentrations (pg/ml) were deter-
mined by comparing samples to a standard curve gener-
ated with the kit.
2.4 Inflammation and hyperalgesia testing
Inflammation was induced by subcutaneously injecting
CFA (0.5 mg/ml heat-killed Mycobacterium tuberculosis sus-
pended in an 1:1 oil/saline emulsion; Sigma, St. Louis,
MO) into the plantar surface of one hind paw of each rat
using a 25-gauge hypodermal needle [12]. Inflammation
appeared within 2 h of the injection and peaked between
6–24 h. PWL was tested with a previously described
method [12,13]. Each rat was placed under an inverted
clear plastic chamber on the glass surface of the Paw Ther-
mal Stimulator System (UCSD, San Diego) and allowed
to acclimatize for 30 min before the test. A radiant heat
stimulus was applied to the plantar surface of each hind
paw from underneath the glass floor with a projector
lamp bulb (CXL/CXR, 8 V, 50 W). PWL to the nearest 0.1
sec was automatically recorded when the rat withdrew its
paw from the stimulus. Stimulus intensity was adjusted to
derive a baseline PWL of approximately 10.0 s in naive
animals. Paws were alternated randomly to preclude
"order" effects. A 20-sec cut-off was used to prevent tissue
damage. Four tests were conducted, with a 5-min interval
between each test. Mean PWL was established by averag-
ing the tests.
2.5 Acupuncture Treatment Procedures
To maximize the anti-inflammatory effect and to treat ani-
mals prophylactically, the EA treatment was given twice,
for 20 min each, once immediately after the administra-
tion of CFA and again 2 h post-CFA [3]. EA parameters of
10 Hz, 3 mA, 0.1 ms pulse width, which showed signifi-
cant anti-inflammatory and anti-hyperalgesic effects on
the rat inflammation model in our previous studies [2,3],
were used in the present study.
The equivalent of the human acupoint Huantiao (GB30)
was chosen for bilateral needling based on traditional
Chinese medicine (TCM) meridian theory [14], on its suc-
cessful use in our previous studies, and on studies by oth-
ers [3,15,16]. Based on our previous point-specificity
study [3], EA produced better anti-hyperalgesia at GB30
than at acupoint Waiguan (the fifth acupoint on the Triple
Energizer Meridian, TE 5) on the forepaw or at two non-
specific points, an abdominal point and a point on the
quadriceps opposite to GB30. Waiguan is located dorsally
between the radius and ulna, two units (based on the
standard acupuncture measurement of twelve units
between the transverse cubital crease and the transverse
wrist crease) above the transverse crease of the wrist.
Underneath are the posterior interosseous nerve and the
anterior interosseous nerve. In humans, GB30 is located at
the junction of the lateral 1/3 and medial 2/3 of the dis-
tance between the greater trochanter and the hiatus of the
sacrum; underneath are the sciatic nerve, inferior gluteal
nerve and gluteal muscles [17]. GB30 was located on the
rat's hind limbs using the comparable anatomical land-
marks. After cleaning the skin with alcohol swabs, a dis-
posable acupuncture needle (0.25 mm thickness × 0.5
inch length) was inserted obliquely approximately 0.5
inch deep at GB30 on each of the animal's hind limbs,
and a pair of electrodes was attached to the handles of the
needles. The needles and electrodes were stabilized with
adhesive tape.
EA stimulation was delivered by an electrical stimulator
(A300 Pulsemaster, World Precision Instruments) via an
isolator (A360D Stimulus Isolator, World Precision
Instruments) that delivers steady direct current. This bilat-
eral, cross-limb connection has been used previously by
our team and others with no adverse effects [3,18]. Similar
connections are frequently used in clinic, and no adverse
effects have been reported [19,20].
While the EA frequency was held constant, intensity was
adjusted slowly over the period of approximately 2 min to
the designated level of 3 mA, which is the maximum EA
current intensity that a conscious animal can tolerate [3].
Mild muscle twitching was observed. During EA treat-
ment, each rat was placed under an inverted clear plastic
chamber (approximately 5 × 8 × 11 inches) but was nei-
ther restrained nor given anesthetic. The animals
remained awake and still during treatment and showed
no observable signs of distress. For sham treatment con-
trol, acupuncture needles were inserted bilaterally into
GB30 without electrical stimulation or manual needle
manipulation. This procedure produced no anti-hyperal-BMC Complementary and Alternative Medicine 2008, 8:20 http://www.biomedcentral.com/1472-6882/8/20
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gesic effect on this animal model in our previous study
[3]. Since it is comparable to the treatment procedure but
lacks therapeutic effect, we used it as sham control in this
study.
2.6 Immunohistochemistry
Rats in experiment 4 were deeply anesthetized after EA
treatment with sodium pentobarbital (60 mg/kg, i.p.) and
immediately perfused transcardially with 4% paraformal-
dehyde (Sigma) in 0.1 M phosphate buffer (PB) at pH 7.4.
The hypothalamus was removed, immersed in the same
fixative for 2 h at 4°C, and transferred to 30% sucrose (w/
v) in PB saline (PBS) overnight for cryoprotection. Forty
micron-thick sections were cut on a cryostat and were
double-stained for p-NR1 and CRH using the immunoflu-
orescence method. Sections were blocked in PBS with
10% normal donkey serum for 60 min, incubated over-
night at room temperature with a mixture of goat polyclo-
nal antibody against CRH (Santa Cruz Biotechnology,
Inc., 1:100) and rabbit polyclonal antibody against P-NR1
(Upstate, Serine 896, 1:100). After three 10-minute wash-
ings in PBS, sections were incubated in a mixture of CY2-
conjugated donkey anti-rabbit (1:100, Jackson Immu-
noResearch Laboratories) and CY3-congugated donkey
anti-goat (1:100) for 1 h at room temperature. Control
sections were similarly processed, except that the primary
antisera were omitted. The stained sections were mounted
on gelatin-coated slides, coverslipped with aqueous
mounting medium (Biomeda Corp., CA) and examined
under a Nikon fluorescence microscope. Control sections
without primary antiserum showed no immunoreactive
staining.
2.7 Data Analysis
For clarity, plasma ACTH level data are presented as per-
cent changes of the baseline level: [(level2–5 h-levelbaseline)/
levelbaseline] × 100%. Paw thickness data were presented as
mean ± SEM. PWL data are presented as mean ± SEM or
(PWL2–5 h - PWLbaseline)/PWLbaseline × 100%. Data were
analyzed using analysis of variance (ANOVA) with
repeated measures followed by post-hoc Tukey's multiple
comparisons (GraphPad InStat). P < 0.05 was set as the
level of statistical significance.
3. Results
3.1 EA increased plasma levels of ACTH in inflamed rats
As shown in Figure 1, the plasma ACTH levels of the EA-
treated inflamed rats were significantly higher 5 h post-
CFA injection than those of sham-treated inflamed rats.
The plasma ACTH levels of sham-treated inflamed rats did
not show significant change from baseline during the
same period. In contrast to CFA-inflamed rats, EA treat-
ment of uninflamed rats produced no significant changes
in plasma ACTH level. CFA-induced inflammation alone
did not cause significant plasma ACTH changes.
3.2 ACTH (11–24) blocked EA anti-edema but not EA anti-
hyperalgesia
We previously reported that EA significantly inhibits
edema compared to sham EA control in CFA-injected rats
[2,4]. Figure 2 shows that paw thickness in rats with EA
plus vehicle was significantly less than that in rats with
sham EA plus vehicle 5 hr post-CFA injection, confirming
that EA significantly inhibited edema compared to sham
control. Paw thickness in rats with sham EA plus ACTH
(11–24) was not different from that in rats with sham EA
plus vehicle, indicating that ACTH (11–24) had little
effect on edema. However, paw thickness in EA-treated
rats plus ACTH (11–24) was not different from that in
sham EA rats plus vehicle, indicating that ACTH (11–24)
blocked EA anti-edema.
Figure 3 shows the effects of ACTH(11–24) on EA-produced
anti-hyperalgesia. Before CFA, overall mean baseline PWL
to noxious heat stimuli was similar in all groups of rats
(from 9.81 to 10.17 sec), and there was no significant dif-
ference in PWLs between left and right hind paws. Follow-
ing injection of CFA, PWL of the injected paw was
significantly less than that of the contralateral hind paw,
which was unchanged from baseline (data not shown).
EA treatment significantly (P < 0.05) increased PWL of the
injected paw 2 h post-CFA compared to sham EA, indicat-
ing that EA inhibited hyperalgesia. ACTH (11–24) pre-
treatment did not affect EA anti-hyperalgesia in EA-treated
Effects of EA treatment on plasma ACTH levels (% changes  vs baseline, n = 6 per group, mean ± SEM) Figure 1
Effects of EA treatment on plasma ACTH levels (% 
changes vs baseline, n = 6 per group, mean ± SEM). 
EA treatment induced no significant changes of plasma ACTH 
in uninflamed rats. CFA-induced inflammation alone resulted 
in no significant changes in plasma ACTH levels. EA treat-
ment in inflamed rats significantly increased ACTH levels 
compared to sham EA. *P < 0.05 compared to sham EA.BMC Complementary and Alternative Medicine 2008, 8:20 http://www.biomedcentral.com/1472-6882/8/20
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rats and showed no effect on hyperalgesia in control rats
with sham EA.
3.3 Astressin blocked EA anti-edema but not EA anti-
hyperalgesia
Figure 4 shows that EA plus vehicle significantly decreased
paw thickness compared to sham EA plus vehicle, indicat-
ing that EA inhibited edema. However, EA plus astressin
did not significantly alleviate hind paw edema compared
with the sham EA rats plus vehicle, indicating that ast-
ressin blocked the EA-produced anti-edema effect. Sham
EA plus astressin did not significantly change hind paw
edema compared with that of sham EA rats plus vehicle,
indicating that astressin had little effect on edema.
Figure 5 shows the effects of astressin on EA-produced
anti-hyperalgesia. PWL of the injected paw was signifi-
cantly shorter compared to baseline while contralateral
PWL did not change (data not shown). EA treatment sig-
nificantly (P < 0.05) increased PWL of the injected paw 2
h post-CFA compared to sham EA, demonstrating that EA
inhibited hyperalgesia. Astressin pretreatment partially
inhibited EA anti-hyperalgesia but had no effect on hyper-
algesia in sham control rats.
3.4 EA activated CRH-containing neurons in the PVN
Double immunofluorescence labeling showed that EA
induced phosphorylation of NR1 subunit of the NMDA
receptor in the PVN. Seventy-three percent of phosphor-
ylated NR1 staining was localized in the CRH-containing
neurons. This indicates that EA mainly activated CRH-
containing neurons in the PVN. Some neurons were sin-
gle-labeled with CRH, suggesting that they were not acti-
vated by EA (Figure 6). Untreated naive rats did not show
NR1 phosphorylation in the PVN. See Figure 6.
4. Discussion
The present study found that EA activates CRH-containing
neurons in the PVN. The PVN is a pivotal nucleus that
Effects of astressin, a CRH receptor antagonist, on EA-pro- duced inhibition of edema (n = 7 per group, mean ± SEM) Figure 4
Effects of astressin, a CRH receptor antagonist, on 
EA-produced inhibition of edema (n = 7 per group, 
mean ± SEM). All rats were CFA-inflamed. Note that ast-
ressin prevented EA-produced inhibition of edema 5 hr post 
CFA. * P < 0.05 compared to vehicle plus sham EA.
Effects of ACTH(11–24) on EA-produced inhibition of hyperal- gesia (n = 7 per group, mean ± SEM) Figure 3
Effects of ACTH(11–24) on EA-produced inhibition of 
hyperalgesia (n = 7 per group, mean ± SEM). Note that 
EA significantly inhibited hyperalgesia 2 h post-CFA, and 
ACTH(11–24) did not prevent EA-produced inhibition of 
hyperalgesia. * P < 0.05 compared to vehicle plus sham EA.
Effects of ACTH(11–24), an ACTH receptor antagonist, on EA- produced inhibition of edema (n = 7 per group, mean ± SEM) Figure 2
Effects of ACTH(11–24), an ACTH receptor antago-
nist, on EA-produced inhibition of edema (n = 7 per 
group, mean ± SEM). All rats were CFA-inflamed. Note 
that ACTH(11–24) prevented EA-produced inhibition of edema 
5 h post CFA. Edema was determined by increased paw 
thickness (mm). * P < 0.05 compared to vehicle plus sham 
EA.BMC Complementary and Alternative Medicine 2008, 8:20 http://www.biomedcentral.com/1472-6882/8/20
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responds to various stimuli including stress [21]. How-
ever, as discussed below, the EA procedures used in this
study have little stress effect. Thus, the neuron activation
in the PVN of EA-treated rats is considered a specific
response to EA, not a general stress response. Previous
study also demonstrates that EA significantly activates the
PVN [22]. Our data further show that EA-activated neu-
rons in the PVN contain CRH, which indicates that EA
treatment may induce CRH secretion. The secreted CRH
acted on CRH receptors to increase ACTH release, which
is supported by the data showing that EA significantly
increases plasma ACTH levels in CFA-inflamed rats com-
pared to sham EA. These data are consistent with our
recent report that EA increases endogenous corticosterone
secretion [4]. The secreted CRH and ACTH activated their
respective receptors, leading to the inhibition of edema.
This is evidenced by our experiments on CRH and ACTH
antagonists. Pretreatment with a CRH antagonists, ast-
ressin and an ACTH antagonist, ACTH(11–24), prevented
EA anti-edema. Taken together, these results suggest that
in pathological conditions EA activates the HPA axis to
increase CRH, ACTH, and glucocorticoid secretion and
suppress inflammatory responses.
It should be mentioned that EA significantly increased
plasma ACTH levels in inflamed rats but not in naive rats,
which is consistent with our previous report that EA
increased plasma corticosterone levels in inflamed rats
but did not affect those of naive rats [4]. It is well known
that stress induces higher ACTH plasma levels. So since
rats with persistent inflammation respond to external
stimuli differently than do healthy rats [23], it is possible
that although EA does not produce stress in naive rats it
may induce stress in inflamed rats. However, our previous
study demonstrated that the same stimulation intensity at
acupoint GB30 as that used in this study did not signifi-
cantly change heart rate or blood pressure, both of which
are indicators of stress response, in CFA-inflamed animals
[2]. This suggests that the stress level, if any, induced by
such EA treatment is minimal in inflamed rats. Given
these data, the ACTH level increase in EA-treated CFA rats
was mainly induced by EA treatment and stress caused lit-
tle, if any, of the increase. Moreover, the discrepancy
between inflamed and naive rats in response to the same
EA treatment suggests that EA affects healthy and patho-
logical conditions differently. This is supported by a pre-
vious study reporting that naloxone completely blocked
EA analgesia in healthy rats but partly blocked EA anti-
hyperalgesia in carrageenan-induced inflammatory rats
[23]. Collectively, these studies suggest that EA works dif-
ferently in healthy and pathological conditions.
It is noted that astressin partially blocked EA anti-hyperal-
gesia, suggesting that endogenous CRH play a little part in
EA anti-hyperalgesia. It has been well documented that EA
Effects of astressin on EA-produced inhibition of hyperalgesia  (n = 7 per group, mean ± SEM) Figure 5
Effects of astressin on EA-produced inhibition of 
hyperalgesia (n = 7 per group, mean ± SEM). Note that 
EA significantly inhibited hyperalgesia 2 h post-CFA, and ast-
ressin partially prevented EA-produced inhibition of hyperal-
gesia. * P < 0.05 compared to vehicle plus sham EA.
Photomicrographs showing co-localization of CRH and p- NR1 in the PVN Figure 6
Photomicrographs showing co-localization of CRH 
and p-NR1 in the PVN. A-C: Sections from EA-treated 
naive rats were double-labeled with anti-CRH (red) and anti-
p-NR1 (green). A: CRH-immunoreactive neurons in the 
PVN. B: p-NRI-immunoreactive neurons in the PVN. C: 
Merged graphs of A and B. Small arrows indicate examples of 
double-labeled CRH/p-NR1 neuron (yellow); Arrowheads 
point to single-labeled CRH and p-NR1. The insets in A, B 
and C are higher magnification of the square areas in A, B 
and C, respectively. D: Sections from untreated naive rats 
were signle-labeled with anti-p-NR1 and showed no labeling 
of P-NR1. Scale bars represent 50 µm in A, B, C, and 250 µm 
in D.BMC Complementary and Alternative Medicine 2008, 8:20 http://www.biomedcentral.com/1472-6882/8/20
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induces higher plasma beta-endorphin levels and that
beta-endorphin is involved in pain modulation [24,25].
So, it is hypothesized that EA activates CRH neurons in
the PVN to secret CRH, which in turn stimulates the
release of beta-endorphin to inhibit pain. A previous
study using direct stimulation of the PVN showed that the
PVN was involved in acupuncture analgesia and that
intracerebral pretreatment with antiserum against vaso-
pressin, which is secreted mainly by PVN, attenuated the
effect of acupuncture analgesia [5]. It suggests that PVN-
produced vasopressin may be involved in acupuncture
analgesia. Taken together, these studies suggest that EA
action involves a variety of PVN chemicals.
It is also noticed that ACTH(11–24) did not block EA anti-
hyperalgesia, suggesting that endogenous ACTH plays lit-
tle role in EA anti-hyperalgesia. Previous studies using
HYPOX showed that the pituitary gland was involved in
acupuncture analgesia [7,8]. The discrepancy between
previous studies and ours may be due to the difference in
animal models, inflammatory vs. uninflamed animals,
since EA affects healthy and pathological conditions dif-
ferently, as stated above. Another difference is that we
used antagonists in our study while the previous studies
used HYPOX that took away all pituitary-secreted mole-
cules, including beta-endorphin. Logically, less involve-
ment of CRH and no involvement of ACTH in EA anti-
hyperalgesia suggest that EA may produce anti-hyperalge-
sia by affecting the nervous system. Our recent studies
[26] demonstrate that EA activates brainstem nuclei,
which are involved in descending inhibitory modulation
of spinal transmission of noxious messages, to inhibit the
transmission of noxious messages at the spinal cord. Our
previous studies demonstrate that spinal mu and delta
opioid systems are involved in EA anti-hyperalgesia in the
same inflammatory pain rat model [12].
5. Conclusion
The present study demonstrates that EA activates CRH-
containing neurons to significantly increase plasma ACTH
levels and suppress edema through CRH and ACTH recep-
tors in a rat model of inflammation. EA-produced inhibi-
tion of edema involves the activation of NMDA receptors
in CRH-containing neurons of the paraventricular
nucleus.
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